Stock CRRTF CRESCITA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Crescita Therapeutics Inc. OTC Markets

Equities

CRRTF

CA2258471028

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 02:14:05 2024-04-02 pm EDT 		5-day change 1st Jan Change
0.32 USD -0.16% Intraday chart for Crescita Therapeutics Inc. 0.00% +14.29%
Mar. 13 Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share MT
Mar. 13 Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 9.352 19.29 14.45 13.64 13.49 9.795
Enterprise Value (EV) 1 5.121 11.51 1.342 5.097 6.795 1.661
P/E ratio 3.66 x 10.8 x 397 x -12.2 x 16.5 x -4.9 x
Yield - - - - - -
Capitalization / Revenue 0.56 x 0.86 x 0.92 x 0.81 x 0.57 x 0.56 x
EV / Revenue 0.31 x 0.52 x 0.09 x 0.3 x 0.29 x 0.09 x
EV / EBITDA 4.62 x 1.8 x 0.66 x -10.6 x 4.21 x -1.94 x
EV / FCF -1.94 x 1.97 x 0.35 x -2.23 x -4.36 x 0.81 x
FCF Yield -51.5% 50.7% 285% -44.9% -22.9% 124%
Price to Book 0.49 x 0.91 x 0.68 x 0.66 x 0.64 x 0.52 x
Nbr of stocks (in thousands) 21,016 20,742 20,648 20,983 20,442 19,989
Reference price 2 0.4450 0.9300 0.7000 0.6500 0.6600 0.4900
Announcement Date 3/21/19 3/18/20 3/24/21 3/23/22 3/15/23 3/13/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 16.63 22.34 15.64 16.77 23.52 17.52
EBITDA 1 1.109 6.393 2.019 -0.479 1.613 -0.857
EBIT 1 -0.037 4.968 0.833 -1.496 0.529 -1.956
Operating Margin -0.22% 22.24% 5.33% -8.92% 2.25% -11.16%
Earnings before Tax (EBT) 1 0.649 3.18 0.52 -1.009 0.404 -1.53
Net income 1 2.396 1.855 0.037 -1.105 0.862 -1.986
Net margin 14.41% 8.3% 0.24% -6.59% 3.66% -11.33%
EPS 2 0.1216 0.0865 0.001764 -0.0532 0.0400 -0.1000
Free Cash Flow 1 -2.635 5.838 3.822 -2.286 -1.559 2.059
FCF margin -15.85% 26.13% 24.44% -13.64% -6.63% 11.75%
FCF Conversion (EBITDA) - 91.31% 189.31% - - -
FCF Conversion (Net income) - 314.7% 10,330.07% - - -
Dividend per Share - - - - - -
Announcement Date 3/21/19 3/18/20 3/24/21 3/23/22 3/15/23 3/13/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 4.23 7.78 13.1 8.54 6.7 8.13
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -2.64 5.84 3.82 -2.29 -1.56 2.06
ROE (net income / shareholders' equity) 15.1% 9.25% 0.18% -5.3% 4.14% -9.95%
ROA (Net income/ Total Assets) -0.09% 11.4% 1.94% -3.35% 1.15% -4.61%
Assets 1 -2,599 16.25 1.907 32.95 74.84 43.12
Book Value Per Share 2 0.9000 1.020 1.020 0.9800 1.040 0.9400
Cash Flow per Share 2 0.4100 0.4500 0.6900 0.5400 0.4100 0.4700
Capex 1 0.14 0.22 0.06 0.35 0.23 0.13
Capex / Sales 0.87% 0.96% 0.38% 2.06% 0.97% 0.76%
Announcement Date 3/21/19 3/18/20 3/24/21 3/23/22 3/15/23 3/13/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CTX Stock
  4. CRRTF Stock
  5. Financials Crescita Therapeutics Inc.